Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2NBXR)

• Drug Name: BMY-21950 Drug Info
• Synonyms: Rac-erythro-9,9-Bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyl-1H-tetrazol-5-yl)-6,8-nonadienoic acid sodium salt

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 23665941
  CAS Number: CAS 131177-45-2
  TTD Drug ID: DM2NBXR

Molecule-Related Drug Atlas

Drug(s) Targeting HMG-CoA reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[3]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[4]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[5]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[6]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[7]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[4]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[4]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[9]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2981).
• [2] Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990 Jul;31(7):1271-82.
• [3] A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
• [4] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [5] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [6] Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
• [7] New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
• [8] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [9] Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.